Immutep Limited (IMMP)
NASDAQ: IMMP · Real-Time Price · USD
2.090
+0.020 (0.97%)
Jan 31, 2025, 4:00 PM EST - Market closed

Immutep Revenue

In the fiscal year ending June 30, 2024, Immutep had annual revenue of 3.84M AUD with 9.59% growth. Immutep had revenue of 1.73M in the half year ending June 30, 2024, a decrease of -34.22%.

Revenue (ttm)
3.84M AUD
Revenue Growth
+9.59%
P/S Ratio
n/a
Revenue / Employee
123,932 AUD
Employees
31
Market Cap
313.18M USD

Revenue Chart

* This company reports financials in AUD.

History

Fiscal Year End Revenue Change Growth
Jun 30, 20243.84M336.16K9.59%
Jun 30, 20233.51M-1.21M-25.64%
Jun 30, 20224.71M851.56K22.04%
Jun 30, 20213.86M-9.88M-71.88%
Jun 30, 202013.74M8.10M143.72%
Jun 30, 2019 Pro Pro Pro
Jun 30, 2018 Pro Pro Pro
Jun 30, 2017 Pro Pro Pro
Jun 30, 2016 Pro Pro Pro
Jun 30, 2015 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
UnitedHealth Group 400.28B
Johnson & Johnson 88.82B
Merck & Co. 63.17B
AbbVie 56.33B
Novartis AG 51.72B
AstraZeneca 51.21B
Thermo Fisher Scientific 42.88B
Abbott Laboratories 41.95B
Revenue Rankings